Your browser doesn't support javascript.
loading
Tadalafil and patients preference in the treatment of erectile dysfunction / 中华男科学杂志
National Journal of Andrology ; (12): 1145-1148, 2006.
Article em Zh | WPRIM | ID: wpr-289060
Biblioteca responsável: WPRO
ABSTRACT
ED treatment has changed fundamentally since phosphodiesterase type 5 inhibitor (PDE5-I) came into clinical use. There are three kinds of PDE5-I available at present, Sildenafil, Vardenafil and Tadalafil. Tadalafil distinguishes from the other two by its uniquely long half-life, which lasts 17.5h, which a pharmacodynamic duration of 36h and not influenced by food and alcohol. Thus it may enable ED patients to accomplish a spontaneous intercourse without the need of prior preparation without, which can boost their confidence and self-esteem and, the most important, improve the relationship with their partner. To know patient preference counts quite a lot in optimizing the medication ED treatment.
Assuntos
Texto completo: 1 Índice: WPRIM Assunto principal: Inibidores de Fosfodiesterase / Psicologia / Psicoterapia / Carbolinas / Satisfação do Paciente / Usos Terapêuticos / Tratamento Farmacológico / Tadalafila / Disfunção Erétil Limite: Humans / Male Idioma: Zh Revista: National Journal of Andrology Ano de publicação: 2006 Tipo de documento: Article
Texto completo: 1 Índice: WPRIM Assunto principal: Inibidores de Fosfodiesterase / Psicologia / Psicoterapia / Carbolinas / Satisfação do Paciente / Usos Terapêuticos / Tratamento Farmacológico / Tadalafila / Disfunção Erétil Limite: Humans / Male Idioma: Zh Revista: National Journal of Andrology Ano de publicação: 2006 Tipo de documento: Article